Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
SAXENDA was evaluated for safety in 5 double-blind, placebo controlled trials that included 3,384 overweight or obese adult patients treated with SAXENDA for a treatment period up to 56 weeks (3 trials), 52 weeks (1 trial), and 32 weeks (1 trial) and one trial of 56 weeks in 125 pediatric patients with obesity aged 12 years and older [see Clinical Studies (14.1, 14.2)]
Dose: Load with 100 mcg IV once, then continue a maintenance dose of 50 mcg subcutaneously q6hr
Microdose tirzepatide applies the same lower-dose philosophy to a dual GLP-1/GIP medication pathway
Semaglutide is a once-weekly injection
Issa has served as a consultant and advisor for Eli Lilly and Company
US$ 20.95
US$ 28.01
US$ 28.64
US$ 25.09
US$ 27.41
